3/4 WENT TO A
HEALTH CARE OR
WELLNESS FACILITY 1N
THE LAST

Clal Chains
Sell Pizza Hut

be considered a loan and part a
grant. IFC's investment is its first
in an Israeli company.

Jerusalem - Clal Chains, a sub-
sidiary of Clal Trade, is in ad-
vance negotiations to sell Pizza
Hut in Israel to Jerusalem con-
tractor Shlomo Dhuki. The sale
is subject to the approval of the
Pepsico Corporation, which owns
Pizza Hut. Eliyahu Ben-Amram,
general manager of Clal Trade,
said he expects to sign the agree-
ment in a few weeks.
Mr. Dhuki is mainly engaged
in the real estate field. The con-
tractor is the owner of Dhuki
Penthouse, which among others
constructed the Harel shopping
mall and a hotel in Mevasseret
Zion. About one month ago Clal
Trade negotiated to sell Pizza
Hut to Israel Theaters, but the
companies failed to come to an
agreement. Clal Trade's decision
to sell Pizza Hut is due to losses
from the franchise and also the
company's decision to get out of
the fast food business.

Power Station
For Guatemala

T P1ND
NGER
NIYWHERE,
OWN.

Jerusalem - Ormat will con-
struct a $65 million privately
owned geothermal power station
in Guatemala.
International Finance Corpo-
ration, a World Bank subsidiary
geared toward private sector in-
vestment, will contribute $16 mil-
lion in funding, of which part will

Jerusalem - Teva announced
that the U.S. Food and Drug Ad-
ministration has approved the fil-
ing of multiple sclerosis treatment
Copaxone for review.
Teva's new drug application
was reified in October after the
FDA rejected the original filing in
August, requesting additional in-
formation relating to certain stud-
ies.
"Just as the FDA surprised us
then by rejecting our file, they
have now surprised us by accept-
ing it (to be reviewed) so quickly,"
said Teva CFO Dan Suesskind.
Mr. Suesskind pointed out that
the FDA has up to 60 days to re-
view files but gave its approval
this time within two weeks.
"We are very happy they acted
so swiftly," he said.
If speed is any indication, he
said "we hope to have a product
on the U.S. market by mid-1996."
A presentation of new data on
Copaxone was well received at a
neurological convention in Wash-
ington, he added.
Teva has also filed Copaxone
for approval in the European
Union through the UK Health
Ministry's Medicines Control
Agency (MCA). "We hope to have
European approval even more
quickly (than U.S.)," said Mr.
Suesskind.

LEADING ISRAELI STOCKS
TRADED ON U.S. EXCHANGES

Symbol Name

Exchange

Dec. 27 Nov. 3 Change

SCIXF

Scitex

NASDAQ

'17.50

'15.263

-$1.88

Regular Jewish News Rates

ECILF

ECI Telecom

NASDAQ

'19.75

$21.13

+$1.38

Minimum Ad Size: 12 Column Inches

TEVIY

Teva Pharm

NASDAQ

$38.25

'39.75

+$1.50

IEC

PEC Israel

NYSE
Elbit Computers NASDAQ
Elscint LTD
NYSE

'23.25

$22.38

-$0.88

'19.25

'18.88

-$0.38

'2.50

$2.23

+$0.13

A

TES AND INFORMATION:

ISSUE DATE: December 29, 1995

AD DEADLINE: December 13, 1995

ELBTF

ELT

ELRNF

THE JEWISH NEWS

3.h.12 112.tviith

48

Drug Approved
For Review

9112.am Wi2aITh gait&

For more information, please call your sales rep at 810.354.6060

'10.63

'10.25

50.38

TAD

Elron Electronics NASDAQ
Tadiran
NYSE

'21.38

'22.25

4.88

CMVT

Co mve rse

NASDAQ

'21.88

'24.88

+$3.00

LANTF

Lannet Data

NASDAQ

'27.63

'28.25

4.63

ISL

First Israel Fund NYSE

'10.75

'10.75

4.00

Source: Allen °lender, Prudential Securities,
West Bloornfiekl.